Daxor Corp
DXR
Company Profile
Business description
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA offers unmatched, real-time, precise data via its rapid, hand-held, lab-based system. The company operates as a single business segment centered on the development, commercialization, and support of its proprietary blood volume analysis technology used by healthcare providers.
Contact
107 Meco Lane
Oak RidgeTN37830
USAT: +1 212 330-8500
Sector
Healthcare
Stock type
Defensive
Industry
Medical Instruments & Supplies
Fiscal Year End
31 December 2026
Employees
750
Stocks News & Analysis
stocks
Chart of the Week: BHP’s valuation hits historic levels
BHP and peers are trading as if the copper boom is here to stay.
stocks
3 cheap wide moat growth stocks
4 and 5 star companies that can protect and grow their earnings.
stocks
ASX biotech expands diagnostics portfolio after FDA approval
FDA nod adds another growth driver for ASX share.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,906.40 | 31.90 | 0.36% |
| CAC 40 | 8,140.59 | 50.31 | 0.62% |
| DAX 40 | 25,537.75 | 135.47 | 0.53% |
| Dow JONES (US) | 51,461.90 | 631.21 | -1.21% |
| FTSE 100 | 10,688.47 | 30.34 | 0.28% |
| HKSE | 24,533.46 | 180.32 | -0.73% |
| NASDAQ | 25,978.43 | 3.14 | -0.01% |
| Nikkei 225 | 64,309.10 | 386.10 | 0.60% |
| NZX 50 Index | 13,730.92 | 108.20 | 0.79% |
| S&P 500 | 7,551.81 | 33.92 | -0.45% |
| S&P/ASX 200 | 8,726.80 | 30.30 | 0.35% |
| SSE Composite Index | 3,877.46 | 14.14 | -0.36% |